Eli Lilly
Pays vs peer median
×1.09
+9% premium
Sample
26
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.16 | 20 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.22 | 7 |
| phase 3 | ×1.01 | 5 |
| phase 2 | ×1.07 | 4 |
| discovery | ×0.70 | 4 |
| preclinical | ×1.50 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | DNA delivery platform | Engage Bio | — | unknown | — | $202M |
| 2026 | Verve gene-editing cardiovascular programs | Verve Therapeutics | cardiovascular disease | unknown | $1.0B | $2.3B |
| 2026 | JAK inhibitor (lead small molecule) | Ajax Therapeutics | myelofibrosis | preclinical | — | $2.3B |
| 2026 | dual-payload ADC platform | Unnamed ADC company | oncology | discovery | — | $300M |
| 2026 | DNA delivery platform (non-viral genetic medicines) | Engage Bio | genetic diseases | preclinical | — | $200M |
| 2026 | in vivo cell therapy candidate | Kelonia Therapeutics | multiple myeloma | preclinical | — | $7.0B |
| 2026 | non-viral genetic medicines platform | unnamed DNA delivery biotech | — | preclinical | — | $300M |
| 2026 | Engage Bio genetic medicine program (myelofibrosis) | Engage Bio | myelofibrosis and myeloproliferative neoplasms | unknown | — | $2.3B |
| 2026 | Engage Bio genetic medicines platform | Engage Bio | myelofibrosis and related diseases | preclinical | — | $2.3B |
| 2026 | In vivo cell therapy for multiple myeloma | Kelonia | multiple myeloma | preclinical | — | $7.0B |
| 2026 | Morphomer Tau | AC Immune SA | Alzheimer's disease and other neurodegenerative diseases | preclinical | $10M | $1.7B |
| 2026 | AI-developed oral therapeutics (multiple preclinical programs) | Insilico Medicine | multiple | preclinical | $115M | $2.8B |
| 2026 | ophthalmic gene therapies | Adverum Biotechnologies | AMD/Diabetic retinopathy | unknown | — | $262M |
| 2026 | neurological gene-editing therapies | Verve Therapeutics | neurological diseases | preclinical | $1.3B | $1.3B |
| 2026 | oral obesity treatments | Nimbus Therapeutics | obesity | discovery | — | $1.3B |
How this is computed
For each Eli Lilly deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 26 disclosed deal premiums vs. peer medians. Raw premium 1.090, clamped to [0.7, 1.5].